SynthesisFrontiers in pharmacology2026
The impact of remimazolam on postoperative neurocognitive disorder in elderly surgical patients: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative neurocognitive disorder (PND), including postoperative delirium (POD) and postoperative cognitive dysfunction (POCD), are prevalent and debilitating complications in elderly surgical patients. Remimazolam, a novel ultra-short-acting benzodiazepine with favorable hemodynamic and sedative properties, has not been fully evaluated for its impact on PND. Method: This systematic review and meta-analysis included studies retrieved from PubMed, Embase, Web of Science, and Cochrane library up to February 2026. Eligible studies compared remimazolam with other sedatives in elderly surgical patients and reported POD or POCD incidence. The primary outcome was the incidence of POD/POCD; secondary outcomes included postoperative MMSE scores, intraoperative opioids consumption, duration of post-anesthesia care unit (PACU) and hospital stay, and perioperative complications. Results: Fifteen randomized controlled trials (RCTs) involving 2,226 patients were analyzed. Remimazolam was not statistically associated with reduction in POD incidence on postoperative days 1 or 3, nor did it affect delirium subtypes or duration. However, remimazolam may be associated with a reduced risk of early POCD on days 1, 3, and 5. Remimazolam reduced intraoperative remifentanil consumption and the incidence of perioperative hemodynamic complications (hypotension and bradycardia). MMSE scores were higher on day 7, and no statistically significant differences were observed in postoperative nausea and vomiting, PACU stay, or hospital stay duration. Conclusion: Remimazolam was not associated with a reduction in POD incidence but may offer a protective effect against early POCD in elderly surgical patients. It provides a favorable hemodynamic profile, and its opioid-sparing properties indicate that it may be a viable sedative option in this population, though further well-designed trials are required. Systematic Review Registration: https://inplasy.com/inplasy-2026-4-0037/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.